CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 159 enrolled
Drug / intervention
amisulpride +1 moredrug
Likely dose
amisulpride 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01253421
NCT01253421Phase 1Completed
CompareCT.gov

The Effects of Dopamine on Reward Processing

Mclean Hospital·interventional·Posted Dec 3, 2010·Updated Apr 27, 2018

In Brief

A Phase 1 clinical trial evaluating amisulpride and placebo for Major Depressive Disorder (MDD). Completed, enrolled 159 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effects of a single low dose of the D2/D3 antagonist amisulpride on reward processing. More generally, this study will test the role of dopamine (a naturally occurring brain chemical) in depression. Hypotheses: Administration of a single low dose of the D2/D3 antagonist amisulpride will (1) improve performance in a behavioral task assessing learning from feedback and (2) boost activation in reward-related brain regions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder (MDD)
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 3, 2010
Enrollment StartFeb 1, 2012
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.6 years ago

Interventions

amisulpridedrug

single low-dose pharmacological challenge, 50 mg amisulpride

placebodrug

single-dose placebo capsule